Adaptive Biotechnologies Corporation
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$24.77
Price+0.12%
$0.03
1Y
Price
Market Cap
$3.964b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-46.9%
EBITDA Margin-55.6%
Net Profit Margin-14.4%
Free Cash Flow Margin-46.9%
EBITDA Margin-55.6%
Net Profit Margin-14.4%
Free Cash Flow MarginRevenue
$308.081m
+11.2%
1y CAGR+23.7%
3y CAGR+15.8%
5y CAGREarnings
-$63.854m
-7.3%
1y CAGR+28.2%
3y CAGR+18.0%
5y CAGREPS
-$0.41
-5.1%
1y CAGR+29.8%
3y CAGR+8.4%
5y CAGRBook Value
$150.662m
$640.678m
Assets$490.016m
Liabilities$410.499m
DebtDebt to Assets
64.1%
-11x
Debt to EBITDAFree Cash Flow
-$29.535m
+39.7%
1y CAGR+43.7%
3y CAGR+36.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company